For US residents only.

How Treatment May Help

Signifor® LAR (pasireotide) for injectable suspension

How Signifor LAR for Injectable Suspension Was Studied

Study 1:

Results of a study of people who either had at least 1 pituitary surgery or did not have pituitary surgery and who had never taken medication for acromegaly

31.3%

had GH <2.5 µg/L and normalized IGF-1 after 12 months on Signifor LAR

vs

19.2%

on another somatostatin analog. (The people in this group did not take the maximum dose of the somatostatin analog during the study.)

98%

of people with acromegaly on Signifor LAR had either a reduction in the volume of their pituitary tumor or no change during the study

  • The median change in tumor volume was a reduction of 39.8%
  • The change in tumor volume for these people ranged from a reduction of 97.6% to an increase of 16.9%

Reductions in ring sizes, and other symptoms—such as headache, fatigue, perspiration, tingling in hands or feet, and joint pain—were noted in patients taking either Signifor LAR or another somatostatin analog.

Study 2:

Results of a study of people with acromegaly whose acromegaly was not controlled on another somatostatin analog1

The people in this study showed a history of not responding to treatment with their current somatostatin analog.

15.4%

who took 40 mg of Signifor LAR every 4 weeks had GH <2.5 μg/L and normalized IGF-1 after 6 months

vs

0%

who continued taking another somatostatin analog they had taken for at least 6 months before starting the study. (Approximately 75% of the people in this group did not take the maximum dose of the somatostatin analog they took during the study.)

20%

who took 60 mg of Signifor LAR every 4 weeks had GH <2.5 μg/L and normalized IGF-1 after 6 months

vs

0%

who continued taking another somatostatin analog they had taken for at least 6 months before starting the study. (Approximately 75% of the people in this group did not take the maximum dose of the somatostatin analog they took during the study.)

81%

of people with acromegaly who took 40 mg of Signifor LAR every 4 weeks had either a reduction in the volume of their pituitary tumor or no change during the study

  • The median change in tumor volume was a reduction of 10.4%. The change in tumor volume for these people ranged from a reduction of 74.5% to an increase of 19.4%

70%

of people with acromegaly who took 60 mg of Signifor LAR every 4 weeks had either a reduction in the volume of their pituitary tumor or no change during the study

  • The median change in tumor volume was a reduction of 6.3%
  • The change in tumor volume for these people ranged from a reduction of 66.7% to an increase of 14.5%

Imagery supplied by Getty Images